Overview

A Safety, Tolerability, and Pharmacokinetic Study of NIP292 in Healthy Normal Subjects

Status:
Recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
This study is being conducted to evaluate the safety and tolerability of single ascending and multiple ascending oral doses of NIP292 tablets administered following an overnight fast in healthy adult subjects.
Phase:
Phase 1
Details
Lead Sponsor:
The National Institutes of Pharmaceutical R&D Co. Ltd, China